Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Am J Hematol. 2022 Nov;97(11):1398-1403. doi: 10.1002/ajh.26706. Epub 2022 Sep 12.
Marginal zone lymphoma (MZL) is commonly underrepresented in clinical trials collectively studying mostly nodal indolent lymphomas.In this manuscript we propose new inclusion and response criteria defined by MZL subtype and disease location for those with extranodal MZL. Progression of disease within 24 months is associated with poor outcomes in MZL and future studies should assess the efficacy of novel agents in this population.
边缘区淋巴瘤（MZL）在共同研究大多数结内惰性淋巴瘤的临床试验中通常代表性不足。在本研究中，我们提出了新的纳入和缓解标准，根据结外 MZL 的 MZL 亚型和疾病部位进行定义。24 个月内疾病进展与 MZL 的不良预后相关，未来的研究应评估新型药物在该人群中的疗效。
